Adicet bio announces first patient dosed in the phase 1 clinical trial of adi-270 in metastatic/advanced clear cell renal cell carcinoma

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in the phase 1 clinical trial evaluating adi-270 in patients with metastatic/advanced ccrcc. “dosing the first patient in our phase 1 trial of adi-270 in metastatic/advanced ccrcc is a significant milestone for adicet as w.
ACET Ratings Summary
ACET Quant Ranking